NEC and Transgene Announce a Collaboration in the Field of Individualized Cancer Immunotherapy, Leveraging NEC's AI and Transgene’s myvac™ Platform
NEC Corporation (NEC)(TOKYO:6701) and Transgene (Euronext Paris:TNG) today announced the signing of a Memorandum of Understanding (MOU) for a strategic collaboration aimed at the treatment of solid cancers. The companies will cooperate in clinically assessing the predictive capabilities of NEC’s artificial intelligence (AI) and the therapeutic potential of Transgene’s myvac™ MVA-based viral vector platform in an individualized immunotherapy for the treatment of solid cancers. The experimental products from this collaboration are expected to enter clinical trials in 2019.
NEC and Transgene will co-invest in the first stage of development of an individualized immunotherapy, which includes clinical trials focusing on ovarian cancer and HPV-negative head and neck cancer.
Immunotherapy is rapidly becoming the treatment of choice to fight cancer as it activates the patient’s own immune system to attack cancer cells.
NEC and Transgene have capitalized on the recent progress in AI and advances in genome sequencing to create individualized immunotherapy, which is adapted to the unique characteristics of each patient’s mutational landscape as well as their predicted immune responses. The product is based on a viral vector (MVA) developed by Transgene with a proven clinical safety track record and is known for its efficient immunogenicity and anti-tumor efficacy in patients.
The viral vector will be used to target neoantigens identified using NEC’s proprietary algorithm. NEC has been developing solutions in the drug discovery field for close to two decades. NEC’s neoantigen prediction system was developed and validated based on publicly available databases, as well as internal wet lab datasets, some of which were already used to identify clinically relevant antigens in other oncology indications.
These planned clinical trials leverage the world-leading expertise and technologies of a network of companies and research centers, including:
- NEC’s cutting-edge AI technology, “NEC the WISE”, for identifying and prioritizing patient-specific neoantigens, and
- Transgene’s unrivaled MVA-based, viral vector technology and the myvac™ platform.
“The emerging personalized medicine field holds great potential for the application of NEC’s core technology, and we are pleased to be working with Transgene with the goal of developing state-of-the-art personalized immunotherapies,” said Motoo Nishihara, Senior Vice President, Head of NEC Laboratories.
“Engaging the body’s own immune system in the fight against cancer has shown great promise and sparked unprecedented interest among oncology drug makers. This makes it imperative for NEC to become part of the immunotherapy race as soon as possible,” said Osamu Fujikawa, Senior Vice President, Business Innovation Unit, NEC Corporation.
“This collaboration brings together artificial intelligence and our expertise in viral vector engineering to enable the development of a truly innovative treatment based on the myvac™ platform. We believe that our collaboration with NEC will allow us to provide an efficacious and robust therapy for the many patients who have solid tumors and could benefit from this cutting-edge individualized approach, and to successfully advance the development of the myvac™ platform to the market” said Éric Quéméneur, Pharm.D., Ph.D., Executive VP, Chief Scientific Officer of Transgene.
Joseph Jasper, +81-3-3798-6511
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
PMC Group International Announces Acquisition of Product Line from Solvay, SA16.1.2019 00:33 | Pressemelding
PMC Ouvrie SAS, France, a wholly owned subsidiary of PMC Group International Inc., which is an independent arm of PMC Group Inc., announced the acquisition of a hydrocolloid product line from the Belgium based Solvay, SA. These products will be sold globally to the home and personal care (HPC), industrial and coatings markets under the trade names Rhodicare CFT, Rhodicare D, Rhodicare H, Rhodicare S, Rhodicare T, Rhodicare XC, Rhodopol 23, Rhodopol G, Rhodopol T, Rhodopol TG, Rhodopol Extra 2, and Rhodopol Extra 2 Clear. “The acquisition of these products made by fermentation processes emphasizes our increasing interest in products made by green chemistry and biological processes,” said Dr. Raj Chakrabarti, Head of PMC Group International. “The acquired hydrocolloids fit synergistically with the functional product lines of PMC Ouvrie, which has long been a leading supplier of defoamers to bio-based process technologies,” he added. ABOUT PMC PMC Group is a US based growth oriented, dive
TurbineAero, Inc. Announces Acquisition of APU Piece Part Repair Business from the Triumph Group15.1.2019 23:51 | Pressemelding
TurbineAero, a portfolio company of The Gores Group, announced today the acquisition of the APU piece part repair product line (“RPL”) from Triumph Aviation Services Asia, Ltd. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190115005959/en/ TurbineAero Repair–Asia, APU Operations Team (Photo: Business Wire) The acquisition of this business segment integrates APU piece part repair into the APU Systems MRO in TurbineAero’s Asia facility which increases in-house capabilities, improves turn-times and assures extra cost reduction. Effective immediately, the integration will take place in TurbineAero Asia’s new Thailand based 80,000 square foot facility which will house up to 250 employees and will handle high technological testing, maintenance, repair and overhaul activities for aircraft components and systems for our worldwide customers, including APU MRO, LRUs and APU part repair. “We are delighted to add the APU piece part rep
INDYCAR Names NTT as Entitlement Sponsor of IndyCar Series15.1.2019 17:20 | Pressemelding
INDYCAR announced today during the North American International Auto Show that global information technology and communications leader NTT has signed a multi-year agreement to become the IndyCar Series Title Partner. In addition, NTT becomes the Official Technology Partner of INDYCAR, the IndyCar® Series, Indianapolis Motor Speedway, the Indianapolis 500 and NASCAR’s the Brickyard 400 beginning in 2019. INDYCAR will partner with NTT to deliver digital innovations that enhance the fan experience. These innovations include the evolution of INDYCAR’s mobile application and adoption of NTT’s proprietary Smart Platform to support the sport and its venues in delivering better insights into the racing series. “NTT is proud to be associated with INDYCAR and accelerate the future of smart racing. Technological innovations have the potential to change the sport and fan experience drastically,” said Jun Sawada, President and CEO of NTT. “NTT, along with our partners, aims to bring the Smart World
MobileIron Recognized as a Partner in Google Led Android Enterprise Recommended Program for Enterprise Mobility Management Providers15.1.2019 17:20 | Pressemelding
MobileIron (NASDAQ:MOBL), the secure foundation for modern work, today announced that it has been recognized by Google™ as a partner in its Android Enterprise Recommended program for Enterprise Mobility Management (EMM) providers. Android™ Enterprise Recommended validates those EMM solutions that meet an elevated set of requirements defined by Google, delivering advanced Android Enterprise features that are supported by highly knowledgeable teams specializing in modern Android security and management. “Enterprise transformation will be central to the second decade of Android computing. Offerings like Android Enterprise Recommended, OEM Config, and Google Play Protect create the perfect storm to support the millions of Android devices that are increasingly making their way to the enterprise,” said Simon Biddiscombe, CEO, MobileIron. “MobileIron is pleased to be a partner in the Android Enterprise Recommended program for EMMs. We are confident that our expertise in endpoint and device se
CSC Extends Fund Administration Reach into Asia Pacific15.1.2019 15:00 | Pressemelding
CSC has extended their private equity and real estate fund administration services into Asia. Third-party oversight of private equity and real estate funds is increasing due to the growing demand from investors for greater transparency and help navigating the regulatory requirements in this dynamic landscape. “A number of factors are creating opportunities in the private equity market in Asia, including strong deal growth, increasing reporting demands from investors, and pressure to commit unspent capital,” says Bill Popeo, president of CSC’s Global Financial Markets business. Liam McHugh, Fund Administration managing director, is leading the efforts in Asia, with office locations in Singapore, Hong Kong, and Shanghai. Prior to joining CSC, McHugh served in various executive capacities at Apex Fund Services and Equinoxe Alternative Investment Services in the APAC region and Ireland. “CSC’s private ownership status ensures the stability that is required of a service provider in a fragme
UAEREP’s First Cycle Awardees Present Outstanding Final Project Results At the 3rd IREF15.1.2019 14:29 | Pressemelding
The UAE Research Program for Rain Enhancement Science’s 3rd International Rain Enhancement Forum (IREF) today featured the final project results of its 1st Cycle awardees at the 2019 Abu Dhabi Sustainability Week (ADSW). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190115005523/en/ 3rd International Rain Enhancement Forum Reveals Results of the Researches of its First Cycle (Photo: AETOSWire) In the presence of a distinguished audience of VIP dignitaries, diplomats, stakeholders and scientists, Dr Linda Zou, Professor Volker Wulfmeyer, Professor Masataka Murakami, presented the final results of innovative research advancing rain enhancement science in the UAE and beyond. The three awardees that presented the successful outcomes of original research projects completed within a 3-year time scale are: Professor Linda Zou, a Professor at the Khalifa Institute of Science and Technology, has fabricated, tested and validated nove